{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-23-000003","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.419733+00:00","generated_at":"2026-06-18T21:24:33.377530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Altimmune Q4 2022 net loss $21.7M; cash $184.9M; pemvidutide obesity interim readout expected March 2023","bullets":["Net loss for Q4 2022 was $21.7M ($0.43 per share) vs $23.9M ($0.57) in Q4 2021; revenue negligible.","Cash, cash equivalents and short-term investments totaled $184.9M at December 31, 2022.","R&D expenses $19.2M in Q4 2022, including $13.4M for pemvidutide and $1.9M for HepTcell.","MOMENTUM Phase 2 obesity trial 24-week interim readout expected in March 2023; Phase 2b NASH trial initiation expected mid-2023.","HepTcell Phase 2 enrollment >90% complete; data readout expected first half 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-23-000003","json":"https://secwatch.observer/filing/0001326190-23-000003.json","markdown":"https://secwatch.observer/filing/0001326190-23-000003.md","text":"https://secwatch.observer/filing/0001326190-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000003/0001326190-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000003/alt-20230228x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:24:33.377530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d04fd97fcdbdf1aecb6f03e92f83bb5c8af056c","claim":"Altimmune, Inc. reported the three months ended December 31, 2022 results: net income $21.7 million, EPS $0.43 net loss per share.","evidence_excerpt":"Net loss for the three months ended December 31, 2022 was $21.7 million, or $0.43 net loss per share, compared to a net loss of $23.9 million, or $0.57 net loss per share, in the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000003/0001326190-23-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Net income","value":"$21.7 million"},{"label":"EPS","value":"$0.43 net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}